Logo image
Tumor Hypoxia Regulates Forkhead Box C1 to Promote Lung Cancer Progression
期刊文章   同儕審查

Tumor Hypoxia Regulates Forkhead Box C1 to Promote Lung Cancer Progression

Yu-Jung Lin, Woei-Cherng Shyu, Chi-Wei Chang, Chi-Chung Wang, Chung-Pu Wu, Hsu-Tung Lee, Liang-Jwu Chen, Chia-Hung Hsieh 和 Jason Chia-Hsun Hsieh
Theranostics, 卷.7(5), 頁碼.1177-1191
01/01/2017
PMID: 28435457
Web of Science ID: WOS:000396574200011

摘要

Animals Antineoplastic Agents - administration & dosage Cell Line, Tumor Cell Movement Cell Proliferation Disease Models, Animal Disease Progression DNA - metabolism Epithelial-Mesenchymal Transition Forkhead Transcription Factors - biosynthesis Heterografts Humans Hypoxia-Inducible Factor 1, alpha Subunit - metabolism Liposomes - administration & dosage Lung Neoplasms - drug therapy Lung Neoplasms - pathology Mice Promoter Regions, Genetic Protein Binding RNA, Small Interfering - administration & dosage Transcriptional Activation Treatment Outcome Tumor Hypoxia
Forkhead box C1 (FOXC1) is a member of the forkhead family of transcription factors that are characterized by a DNA-binding forkhead domain. Increasing evidence indicates that FOXC1 is involved in tumor progression. However, the role of tumor hypoxia in FOXC1 regulation and its impact on lung cancer progression are unclear. Here, we report that FOXC1 was upregulated in hypoxic areas of lung cancer tissues from rodents or humans. Hypoxic stresses significantly induced FOXC1 expression. Moreover, hypoxia activated FOXC1 transcription via direct binding of hypoxia-inducible factor-1α (HIF-1α) to the hypoxia-responsive element (HRE) in the FOXC1 promoter. FOXC1 gain-of-function in lung cancer cells promoted cell proliferation, migration, invasion, angiogenesis, and epithelial-mesenchymal transition . However, a knockdown of FOXC1 in lung cancer cells inhibited these effects. Notably, knockdown of tumor hypoxia-induced FOXC1 expression via HIF-1-mediated FOXC1 shRNAs in lung cancer xenograft models suppressed tumor growth and angiogenesis. Finally, systemic delivery of FOXC1 siRNA encapsulated in lipid nanoparticles inhibited tumor growth and increased survival time in lung cancer-bearing mice. Taken together, these data indicate that FOXC1 is a novel hypoxia-induced transcription factor and plays a critical role in tumor microenvironment-promoted lung cancer progression. Systemic FOXC1 blockade therapy may be an effective therapeutic strategy for lung cancer.

檔案與連結 (1)

url
https://doi.org/10.7150/thno.17895檢視
已出版(紀錄版本) 開放

相關連結

詳細資料

Logo image